Asunto(s)
Enfermedades de la Córnea/diagnóstico , Enfermedades del Prematuro/diagnóstico , Queratitis/diagnóstico , Enfermedades de la Córnea/complicaciones , Enfermedades de la Córnea/congénito , Esotropía/complicaciones , Esotropía/congénito , Esotropía/diagnóstico , Femenino , Humanos , Recién Nacido , Enfermedades del Prematuro/patología , Queratitis/complicaciones , Queratitis/congénito , Retinitis Pigmentosa/complicaciones , Retinitis Pigmentosa/congénito , Retinitis Pigmentosa/diagnóstico , Trastornos de la Visión/congénito , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/etiologíaAsunto(s)
Anomalías del Ojo/complicaciones , Glaucoma/congénito , Glaucoma/diagnóstico , Glaucoma/etiología , Disco Óptico/anomalías , Coloboma/complicaciones , Coloboma/diagnóstico , Diagnóstico Diferencial , Anomalías del Ojo/diagnóstico , Humanos , Lactante , Masculino , Disco Óptico/diagnóstico por imagen , Nervio Óptico/anomalíasRESUMEN
Posterior capsule opacification (PCO) is the most common complication after cataract surgery, with an incidence of 30%. It tends to be considered a normal event in the natural history of cataract surgery. Better understanding of its pathophysiology and advancement of intraocular lens material and design along with the improvement of phacoemulsification technique have contributed to decrease the incidence of PCO. Although treatment by Nd: YAG laser posterior capsulotomy is quick and non-invasive, the opening of the posterior capsule may be associated with numerous complications. Prevention remains the best measure for controlling this pathology.
Asunto(s)
Opacificación Capsular , Adulto , Opacificación Capsular/diagnóstico , Opacificación Capsular/patología , Opacificación Capsular/prevención & control , Opacificación Capsular/terapia , Extracción de Catarata/efectos adversos , Niño , Diagnóstico Diferencial , Humanos , Terapia por LáserRESUMEN
OBJECTIVE: Assessment of cancer screening in the context of venous thromboembolic disease (VTE) remains controversial. We tried to characterize a population at high risk of developing cancer among patients suffering from VTE. METHOD: We conducted a retrospective ancillary case-control study among patients with VTE who later had a positive diagnosis of cancer. We assessed the association of cancer with characteristic features of VTE and with the results for four biological markers. RESULTS: Our population included 142 patients (53% men, median age 71 years). Two years after VTE, 24 patients (17%) had cancer. Median values for D-dimers, fibrin monomers and SP-selectin were significantly higher among patients who developed cancer. Logistic regression enabled us to identify two parameters targeting patients with a high risk of cancer: bilateral venous thrombosis (OR: 4.41, 95%CI: 1.41-13.78, P=0.01) and D-dimers superior to 3.8 µg/mL (OR: 3.68, 95%CI: 1.36-9.94, P=0.01). The information provided by these two characteristics was additive; 58% of patients in our population who had both factors developed cancer. CONCLUSION: Bilateral venous thrombosis and D-dimers superior to 3.8 µg/mL are highly associated with carcinoma. This result requires a prospective validation. It could be useful in limiting the screening process to the population most at risk.
